Drug Trial Radar · NCT05779163
A Phase I/II Clinical Trial of LBL-033 in the Treatment of Advanced Malignant Tumors
Last checked: Nov 19, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Apr 14, 2023
Primary completion
Apr 3, 2025
Study completion Apr 3, 2025
Sponsor
- Lead sponsor
- Nanjing Leads Biolabs Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is an open and multicenter phase I/II clinical study, which aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and effectiveness.
Conditions
- Advanced Malignant Tumors
Interventions
LBL-033 for InjectionDrug
Initial dose - MTD; Q2W; intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicities(DLT)Time frame: At the end of Cycle 1(28 days after the first prespecified dose)
- Maximum tolerated dose (MTD)Time frame: At the end of Cycle 1(28 days after the first prespecified dose)
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Fujian Cancer Hospital
Fuzhou, Fujian, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, China
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China
West China Second University Hospital,Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.